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Abstract
Background: we project incidence and prevalence of stroke in the UK and associated costs to society to 2035. We include
future costs of health care, social care, unpaid care and lost productivity, drawing on recent estimates that there are almost
1 million people living with stroke and the current cost of their care is £26 billion.
Methods: we developed a model to produce projections, building on earlier work to estimate the costs of stroke care by
age, gender and other characteristics. Our cell-based simulation model uses the 2014-based Office for National Statistics
population projections; future trends in incidence and prevalence rates of stroke derived from an expert consultation exercise;
and data from the Office for Budget Responsibility on expected future changes in productivity and average earnings.
Results: between 2015 and 2035, the number of strokes in the UK per year is projected to increase by 60% and the number of
stroke survivors is projected to more than double. Under current patterns of care, the societal cost is projected to almost treble
in constant prices over the period.The greatest increase is projected to be in social care costs—both public and private—which
we anticipate will rise by as much as 250% between 2015 and 2035.
Conclusion: the costs of stroke care in the UK are expected to rise rapidly over the next two decades unless measures to
prevent strokes and to reduce the disabling effects of strokes can be successfully developed and implemented.
Keywords: costs, incidence, older people, stroke, prevalence, projections
Key points
• We project that stroke incidence in the UK will increase by 60% per year between 2015 and 2035.
• Stroke prevalence is projected to increase by 120% between 2015 and 2035.
• Between 2015 and 2035, societal costs associated with increases in incidence and prevalence will almost treble in constant
prices.
• Social care costs will increase at a greater rate, 270%, than will health care costs, unpaid care costs or lost productivity, after
adjusting for inflation.
D
o
w
n
lo
a
d
e
d
 fro
m
 h
ttp
s
://a
c
a
d
e
m
ic
.o
u
p
.c
o
m
/a
g
e
in
g
/a
d
v
a
n
c
e
-a
rtic
le
-a
b
s
tra
c
t/d
o
i/1
0
.1
0
9
3
/a
g
e
in
g
/a
fz
1
6
3
/5
7
0
7
4
5
7
 b
y
 g
u
e
s
t o
n
 2
9
 J
a
n
u
a
ry
 2
0
2
0
D.King et al.
Introduction
Over 113,000 individuals suffer a stroke each year in the
UK, and there are around 1million stroke survivors currently
[1,2].These numbers are increasing due to population ageing
and because treatment improvements lead to better survival
rates. The number of strokes each year in Europe is projected
to increase by 34% between 2015 and 2035 [3].
In addition to the significant impacts on individuals who
suffer a stroke and their families, there can be substantial
health and social care service implications. The current UK
annual societal cost of stroke is £25.6 billion [4].
Projecting future epidemiological and economic impacts
of stroke provides a platform for planning prevention, treat-
ment and support services. Projected expenditure associated
with these activities can inform decision-making on service
funding.
We present projections of future incidence and prevalence
of stroke among people aged 45 and over in the UK, and
associated costs of treatment and support. Our estimate of
future costs includes healthcare (prevention and treatment),
social care, costs of contributions from family and friends
supporting stroke survivors, and productivity losses due to
stroke survivors leaving or interrupting employment. Our
projections use official Office for National Statistics (ONS)
population projections and incorporate results from expert
consultation on future incidence and prevalence of stroke.
Sensitivity analyses around the ONS principal population
projection and expert consultation results are also presented.
Methods
Future incidence, prevalence and cost of stroke are estimated
using a cell-based simulation model in Excel. The model
structure has been used previously to project demand and
associated expenditure for long-term care [5].
Data
Current stroke costs in the UK are estimated elsewhere,
and detailed description of methods is provided there [4].
Projecting costs into the future uses ONS 2014-based
population projections [6], future trends in incidence and
prevalence rates from a consultation exercise with 11 stroke
experts, the balance between public and private social care
from the Personal Social Services Research Unit (PSSRU)
projections model [5], and expected future changes in
productivity and average earnings from the 2018 Office for
Budget Responsibility (OBR) Fiscal Sustainability Report
[7].
Overview of the model
Our model has 2015 as its base year. Projections of future
societal costs of stroke are estimated for 2025 and 2035.
Further details of the model design and data sources appear
in supplementary material, Appendix 1.
Incidence and prevalence
The model first estimates the numbers of new strokes (inci-
dence) and stroke survivors (prevalence) for each age band
and gender. Three key studies reporting stroke incidence
were found after a focused review of UK studies [1,8,9]. For
our central case estimates, we used as estimated stroke inci-
dence in 2015 the mid-point estimate of 117,600. A further
three-key studies reported stroke prevalence [2,10,11]. Our
modelling used the prevalence estimate, 950,200, from the
largest of these studies [2].
Health and social care costs
We produced separate cost estimates for people in the first
year following stroke and for subsequent years after stroke,
following the approach by the National Guideline Centre
(NGC) and the Sentinel Stroke National Audit Programme
(SSNAP) [12]. We separately estimate health care, social
care (publicly and privately funded), unpaid care and lost
productivity costs.
Unpaid care costs and lost productivity
Data from the Training Caregivers after Stroke (TRACS)
trial [13] and the Longer-Term Stroke (LoTS) Care study
[14] on self-reported carer inputs to personal care and other
supports were used to estimate costs associated with unpaid
care (sometimes called ‘informal care’). TRACS data were
used to generate unpaid care estimates in the first year and
LoTS Care data to estimate unpaid care costs in subsequent
years.
Estimates for 2025 and 2035
Incidence and prevalence
Future increments in incidence and prevalence of stroke were
derived from a consultation with stroke experts. We used
a Delphi-style approach to obtain their views on the level
of annual change in stroke incidence and prevalence rates
in the next 10 years and 11–20 years. Experts approached
had previously worked on epidemiological studies related to
stroke and were aware of relevant evidence and trends related
to both stroke epidemiology and clinical care.
Of the 19 experts contacted, 11 participated. Results of
each round of the consultation appear in supplementary
materials, Appendices 2 and 3. We chose as our central case
the most frequently chosen options after the second (final)
round of the consultation. These are presented in Table 1.
Unit costs of health and social care
Also necessary was an assumption about the rate of increase
in unit costs of health and social care. These services
are highly labour intensive. As such, they are likely to
rise broadly in line with average earnings of professionals
working in these sectors. The OBR assume that average
earnings and productivity will rise by 2% per year in real
terms (i.e. over and above general inflation) [7]. Our central
2
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The future incidence, prevalence and costs of stroke in the UK
Table 1. Assumed annual increments in stroke incidence
and prevalence rates between 2015–2025 and 2025–2035
2015–2025 2026–2035
Incidence Prevalence Incidence Prevalence
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Age 45–64 0.0% 1.0% 0.0% 1.0%
Age 65–74 0.0% 1.5% 0.0% 1.5%
Age 75–84 0.0% 2.0% 0.0% 2.5%
Age 85 and over 0.5% 2.5% 0.5% 3.0%
Source: Expert consultation exercise.
case, therefore, is that health and social care unit costs will
rise by 2% per year in real terms.
Sensitivity analysis
Sensitivity analysis around increases in health and social
care unit costs, trends in population mortality rates and
trends in stroke incidence and prevalence were performed.
A detailed description of these analyses can be found in
supplementary material, Appendix 4.
Results
Primary projection of future cost of stroke
We project stroke incidence will rise from 117,600 in 2015
to 148,700 in 2025 and 186,900 in 2035, an increase of
59% over the total 20-year period 2015 to 2035. We also
project that stroke prevalence will rise from 950,200 in 2015
to 1,424,100 in 2025 and 2,119,400 in 2035, an increase of
123% over the 20-year period. Our central projections are
set out in more detail in Table 2.
Our model projects societal costs of stroke in the UK
will rise from £26 billion in 2015 to £43 billion in 2025
and then to £75 billion in 2035, an increase of 194% over
20 years, in constant 2015 prices. Given projections of UK
GDP, at 2015 prices, of £1873 billion, £2144 billion and
£2641 billion in 2015, 2025 and 2035, respectively [7,15],
our projections are that societal cost of stroke will rise from
1.4% of GDP in 2015 to 2.0% in 2025 and 2.9% in
2035.
Health care costs are projected to rise by 201%, social
care costs by 273%, unpaid care costs by 171% and lost
productivity costs by 136%. It is estimated that private social
care costs will rise at a slightly greater rate than public costs:
278% versus 268%, respectively. These projections are set
out in more detail in Table 3.
Social care costs are projected to rise much more rapidly
in the next 20 years than the health care, unpaid care or lost
productivity costs. This is because the size of the population
aged 75 and over is projected to rise more rapidly than
the population aged 45–75 and social care use is more
prevalent at older ages. That is, social care cost per person
rises much more sharply with age than health, unpaid care
or lost productivity costs. Among people who have survived
ischaemic stroke, annual average social care costs per person
at age 75 and over is more than twice the costs at ages 45–74.
Average annual health costs, however, vary far less by age. As
we would expect, unpaid care costs are significantly higher
for the older age group, while lost productivity costs are not.
Sensitivity analysis
The ONS 2014-based life expectancy variant population
projections are used to show the impact of variant popu-
lation projections on projected incidence, prevalence and
costs. We project stroke incidence will rise between 2015
and 2035 by 66% under the high-life-expectancy variant
and 52% under the low-life expectancy variant in compar-
ison with 59% under the principal projection (our cen-
tral case). Stroke prevalence will rise by 132% under the
high-life expectancy variant and 114% under the low-life
expectancy variant in comparison with 123% under the
principal projection. We further project overall stroke costs
in the UK will rise by 205% under the high-life expectancy
variant and 183% under the low-life expectancy variant
in comparison with 194% under the principal projection
(supplementary material, Appendix 5).
If incidence and prevalence rates in each age band rise
by 1 percentage point per year more than under our central
case described above, stroke incidence will rise by 94%, the
number of stroke survivors aged 45 and over will rise by
171% and overall stroke costs will rise by 257% between
2015 and 2035 (supplementary material, Appendix 5). If the
incidence rate falls by 1 percentage point per year for those
aged 45–84 and by 0.5 percentage point per year for those
aged 85 and over and prevalence rates in each age band rise
by 1 percentage point per year more than under our central
case described above, we estimate stroke incidence will rise
by 30%, stroke prevalence among people aged 45 and over
will rise by 83% and overall costs of stroke will rise by 141%
between 2015 and 2035 (supplementary material, Appendix
6). The variation in projected future costs is greater under
our variant assumptions on future incidence and prevalence
rates than under the ONS variant population projections
(supplementary material, Appendix 7).
Finally, we consider the impact of alternative assumptions
on real annual rise in costs. If costs per person rose by 2.5%
per year in real terms, overall stroke costs would rise from £26
billion in 2015 to £83 billion in 2035, an increase of 224%,
in constant 2015 prices. If costs per person rose by only
1.5% per year in real terms, overall stroke costs would rise
from £26 billion in 2015 to £68 billion in 2035, an increase
of 166%. These projections should be compared with our
central case projection of a rise of 194% in overall costs
between 2015 and 2035. Projections of aggregate costs over
a 20-year period are inevitably highly sensitive to assumed
real annual rise in costs per person.
Discussion
Our projection modelling suggests that, on the basis of
ONS population projections and expert opinion on trends
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D.King et al.
Table 2. Projections of future number of incident and prevalent cases of stroke, age 45 and over, by gender and stroke type,
2015–2035, UK
Gender, type of stroke Incidence Prevalence
2015 2025 2035 2015 2025 2035
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Females
Ischaemic 53,700 66,400 84,300 397,300 594,800 912,500
Haemorrhagic 6400 7900 10,000 41,800 62,700 96,200
Males
Ischaemic 51,700 66,600 82,900 462,500 693,300 1,004,300
Haemorrhagic 5900 7700 9800 48,600 73,300 106,300
Total
Ischaemic 105,300 133,000 167,200 859,800 1,288,100 1,916,900
Haemorrhagic 12,300 15,700 19,700 90,400 136,100 202,600
Total all strokes 117,600 148,700 186,900 950,200 1,424,100 2,119,400
Note: Numbers may not add exactly due to rounding. Source: Expert consultation exercise and authors’ calculations.
Table 3. Projections of future costs of stroke by type of cost (in £million), 2015–2035, age 45 and over, UK
Costs (£m) 2015 2025 2035 % change
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Health care 3400 6900 10,200 200%
Social care—Public 2400 4700 9000 275%
Social care—Private 2700 5400 10,300 280%
Social care—Total 5200 10,100 19,300 270%
Unpaid care 15,600 24,400 42,200 170%
Lost productivity 1500 2300 3500 135%
Total 25,600 42,600 75,200 195%
Note: Numbers may not add exactly due to rounding. Source for 2015 costs: Patel et al . [4], authors’ calculations.
in incidence and prevalence rates, the number of strokes in
the UK per year will increase by 60% between 2015 and
2035 and the number of stroke survivors in the population
will more than double over those 20 years. We project that
over this period societal costs associated with these increases
in incidence and prevalence will almost treble in constant
prices. The greatest increase is projected to be in social care
costs—both public and private—whichmay be over two and
a half times higher in 2035 than in 2015, after adjusting for
inflation.
The survey of experts tended towards a small or no change
in stroke incidence rates rather than a continuing decrease.
This can be interpreted as an expectation that the falling
incidence rate has now levelled out or that contributors to
falling incidence will in future be counterbalanced by other
trends (e.g. rising obesity rates) that increase the likelihood
of stroke. It is helpful to compare our projections, based
on these assumptions, with those made in other studies,
although methodologies differ.
Kingston et al . [16] estimated that stroke prevalence in
England will increase by 84% between 2015 and 2035 from
726,000 to 1,338,000 among those aged 65 and over (as
opposed to 45 and over used in our study). The authors used
a discrete time dynamic microsimulation model (PACSim)
to simulate characteristics of individuals and their probabil-
ity of transitioning into a state of chronic illness over the
period 2014–2035.
A projection of future stroke prevalence in Australia,
using demographic trends only, estimated a 75% increase
between 2011 and 2032 [17]. Thus, while their projection
covers a very similar length of time, it is lower than our
estimate of a 123% increase. One would, however, expect
their estimate to be lower given they assumed no change
in incidence and prevalence rates over time, which seems
unlikely.
Ovbiagele et al . [18] projected that between 2012 and
2030 health care costs associated with stroke in the USwould
increase by 160%. Their model used official population
projections but did not make assumptions on future changes
in incidence or prevalence rates or real increases in unit
costs of care. We made these further assumptions in our
analyses, for the reasons set out earlier, with the consequence
that our model projects health care costs associated with
strokes in the UK for a similar period will increase by
200%.
We assume in our central projections that mortality rates
by age and gender will fall in line with ONS assumptions
and incidence and prevalence rates of stroke will change in
line with the views of experts. We have shown in sensitivity
analyses that our projections are sensitive to these assump-
tions. We hold constant over time the intensity of service
receipt by age, gender, type of stroke and stroke severity. We
do not assume any increase in coverage or quality of services,
since we want to inform future policy by investigating future
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The future incidence, prevalence and costs of stroke in the UK
costs under current policy and practice rather than speculate
about future policy or practice developments. It is likely
that in practice intensity of service receipt by stroke patients
will change due to changes in treatments, such as wider use
of thrombectomy, changes in risk factor profiles within the
population and changes in expectations of treatment and
support of stroke survivors and their families. We have not
made assumptions about such changes here.
We assume that the supply of unpaid care by family and
friends will rise in line with demand as the number of stroke
survivors rises. This is clearly uncertain [19]. If the supply of
unpaid care does not rise in line with demand, formal services
and their associated costs may need to rise more rapidly than
under our projections.
The model estimates costs attributable to stroke. We are
aware, however, that individuals who have a stroke and
survive may have considerable comorbidities. As such, it is
very difficult to distinguish between costs attributable to
stroke and those attributable to concurrent comorbidities
though we have attempted to do so [4].
Particularly concerning are the expected future conse-
quences of strokes for the social care sector, especially given
that funding for social care in parts of the UK is currently so
severely constrained.The scale of projected future costs high-
lights the urgency of addressing future funding arrangements
for social care. Our projections may be helpful, for example,
in informing current debate in England about how to pay
for adult social care.
Effective measures to prevent strokes and treatments to
reduce the disabling effects of stroke have the potential
to reduce future health, well-being and cost impacts of
stroke. These would include thrombectomy for a larger
proportion of people experiencing a stroke. Development
and implementation of measures to prevent strokes and
to reduce disabling effects of strokes will be crucial. This
may likely require increased investment in research to
develop interventions and approaches to implementing them
successfully.
Supplementary data: Supplementary data mentioned in
the text are available to subscribers in Age and Ageing online.
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